Publications by authors named "C Cassieri"
Article Synopsis
- Infliximab and adalimumab are both commonly used medications for treating Crohn's disease and ulcerative colitis, and this study aimed to evaluate their long-term effectiveness and safety in real-life clinical settings.
- A total of 712 patients were reviewed, showing that both treatments maintained clinical remission similarly in Crohn's disease, but infliximab showed better results for ulcerative colitis.
- Adalimumab had a significantly lower rate of adverse events compared to infliximab, making it a potentially safer option for patients.
In this session different problems regarding the pathogenesis of diverticular disease were considered, including "Genetics", "Neuromuscular function abnormalities", "Patterns of mucosa inflammation", and "Impact of lifestyle". The patients affected by diverticular disease have clear genetic pattern, that might predispose to the occurrence of the disease as well as to its complications. Neuromuscular abnormalities may be recognized already at the stage of diverticulosis, and inflammation may explain symptoms occurrence in symptomatic uncomplicated diverticular disease (SUDD) or symptoms persistence after an episode of acute diverticulitis.
View Article and Find Full Text PDFHot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons.
J Gastrointestin Liver Dis
December 2019
Symptomatic Uncomplicated Diverticular Disease (SUDD) is the most common clinical form of Diverticular Disease (DD). The therapy should be aimed at reducing both the intensity and frequency of symptoms as well as preventing complications. The pharmacological treatments include fibers, not absorbable antibiotics (for example rifaximin), anti-inflammatory drugs (for example 5-amino-salycilic acid) and probiotics, alone or in combination with other drugs.
View Article and Find Full Text PDFThe DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study.
J Gastrointestin Liver Dis
December 2019
Background And Aims: The Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification of diverticulosis and diverticular disease (DD) is currently available. It scores severity of the disease as DICA 1, DICA 2 and DICA 3. Our aim was to assess the agreement on this classification in an international endoscopists community setting.
View Article and Find Full Text PDFBackground And Aim: Although rifaximin and mesalazine seem to be effective in treating the majority of people suffering from diverticular disease (DD), some patients still experience symptoms following those treatments. The aim of this study was to assess the efficacy of budesonide MMXTM in managing symptoms and raised fecal calprotectin (FC) in patients with endoscopic diagnosis of DD and not responding to standard treatments.
Methods: We performed a post-hoc analysis of the patients enrolled in the DICA prospective study.